RAPP trades 109.3% below Wall Street's consensus target of $67.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RAPP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Rapport Therapeutics, Inc. Common Stock (RAPP) has a Wall Street consensus price target of $67.33, based on estimates from 5 covering analysts. With the stock currently trading at $32.17, this represents a potential upside of +109.3%. The company has a market capitalization of $1.54B.
Analyst price targets range from a low of $52.00 to a high of $80.00, representing a 42% spread in expectations. The median target of $70.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RAPP trades at a trailing P/E of -11.2x. Analysts expect EPS to grow -39.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PTCTPTC Therapeutics, Inc. | $5.3B | $63.46 | $106.00 | +67.0% | Buy | 49.9x | 26 |
 ACADACADIA Pharmaceuticals Inc. | $3.4B | $19.95 | $32.32 | +62.0% | Buy | 32.4x | 37 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $295.51 | $603.83 | +104.3% | Buy | — | 18 |
 INVAInnoviva, Inc. | $1.5B | $20.50 | $38.00 | +85.4% | Buy | 8.5x | 10 |
 NKTRNektar Therapeutics | $1.4B | $43.58 | $146.00 | +235.0% | Buy | — | 33 |
 LGNDLigand Pharmaceuticals Incorporated | $6.1B | $302.96 | $339.43 | +12.0% | Buy | 32.6x | 18 |
 ARVNArvinas, Inc. | $478M | $7.41 | $14.17 | +91.2% | Buy | — | 26 |
 AXSMAxsome Therapeutics, Inc. | $9.2B | $179.25 | $281.63 | +57.1% | Buy | — | 27 |
 SRRKScholar Rock Holding Corporation | $5.6B | $46.81 | $70.45 | +50.5% | Buy | — | 14 |
 LLYEli Lilly and Company | $1.1T | $1142.85 | $1343.07 | +17.5% | Buy | 31.2x | 45 |
Quick answers to the most common questions about buying RAPP stock.
The consensus Wall Street price target for RAPP is $67.33, representing 109.3% upside from the current price of $32.17. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
RAPP has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $67.33 implies 109.3% upside from current levels.
RAPP's current price is $32.17 with a consensus target of $67.33 (109.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $80 for RAPP, while the most conservative target is $52. The consensus of $67.33 represents the median expectation. These targets typically reflect 12-month expectations.
RAPP is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RAPP stock forecast based on 5 Wall Street analysts shows a consensus price target of $67.33, with estimates ranging from $52 (bear case) to $80 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on RAPP, with a "Buy" consensus rating and $67.33 price target (109.3% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RAPP analyst price targets range from $52 to $80, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $67.33 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.